Carmen Diana Herling

Status: Independent Research Group Leader

Clinic I of Internal Medicine
University Hospital Cologne
Kerpener Str. 62
50937 Cologne

Phone: +49 221/478 85636
Fax: +49 221/478 88847
Nationality: German




Medical School of the Ludwig-Maximilians-University in Munich, Germany (qualification as MD, magna cum laude)


MD thesis: "Characterization of the antitumoral T cell response after AAVmediated gene transfer of TNF-ligands in combination with CD80 into human melanoma cells", Clinical Collaborative Group for Gene- and Immunotherapy, Ludwig-Maximilians-University Munich, Germany (magna cum laude)


Professional and Research Experience

01/2003 -10/2003

Clinical resident at the Ludwig-Maximilians-University Munich, Department of Internal Medicine III, Hematology & Medical Oncology, Munich, Germany

01/2003 - pres.

Member and coworker of the German CLL Study Group DCLLSG (, (co-)investigator in several clinical trials (phase I-III) in the field of chronic lymphocytic leukemia (CLL) and Non-Hodgkin’s-Lymphoma (NHL)

11/2003 - 09/2008

Clinical resident at the University of Cologne, Department of Internal Medicine I, Hematolology & Medical Oncology and Infectious Diseases, Cologne, Germany

2004 - 2009 

 Coordinator of the European Research Initiative on CLL (ERIC,

09/2008 - 01/2011

Postdoctoral fellow at the University of Texas M.D. Anderson Cancer Center, Department of Hematopathology, Research laboratory and Laboratory of Clinical Cytogenetics, Mentor: Lynne Abruzzo MD PhD, Director of the Clinical Cytogenetics Laboratory
Focus: Integration of clinical and genomic/molecular data obtained by array genotyping and gene expression profiling in CLL for clinical outcome prediction and biomarker identification

02/2012 – present

Adjunct assistant professor at the UT M.D. Anderson Cancer Center, Department of Hematopathology

02/2012 – present

Clinician scientist and laboratory PI at the Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany (Laboratory of functional genomics in lymphoid malignancies,  

04/2014 - 05/2015

 Maternal leave


 Board exam (general internal medicine, hematology and medical oncology)


Awardsand Prizes

1997 - 2002

Student scholarship by the Konrad-Adenauer-Foundation, St. Augustin, Germany


Wolfgang Wilmanns Foundation Award (Poster Prize) at the 5th International Symposium on Biological Therapy of Cancer, Munich, Germany


Travel award by the German Academic Exchange Service (DAAD)


Shannon Timmins Fellowship in Leukemia Research




Member of the German Society of Internal Medicine (DGIM)


European Research Initiative on CLL (ERIC)


European Hematology Association (EHA)


American Society of Hematology


List of the five most important publications

  1. Vollbrecht C, Mairinger FD, Koitzsch U, Peifer M, Koenig K, Heukamp LC, Crispatzu G, Wilden L, Kreuzer KA, Hallek M, Odenthal M, Herling CD*, Buettner R* (equal contribution): Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing. PLoS One, 2015 Jun 8; 10(6): e0129544.

  2. Schweighofer CD, Coombes KR, Majewsky T, Barron LL, Lerner S, Sargent RL, O’Brien S, Ferrajoli A, Wierda WG, Czerniak B, Medeiros LJ, Keating MJ, Abruzzo LV: Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in chronic lymphocytic leukemia (CLL): a comparison of CLL and HapMap genotypes. J Mol Diagn, 2013 Mar; 15(2): 196-209.

  3. Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, O'Brien S, Wierda WG, Luthra R, Medeiros LJ, Keating MJ, Abruzzo LV: A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia. PLoS One, 2011; 6(12): e28277.

  4. Schweighofer CD, Huh YO, Luthra R, Sargent RL, Ketterling RP, Knudson RA, Barron LL, Medeiros LJ, Keating MJ, Abruzzo LV: The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. Int J Cancer, 2011 June 1, 128(11): 2759-2764.

  5. Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, Hallek M, Wendtner CM: Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol, 2009 Jan; 144(1): 95-8.